{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:40:16Z","timestamp":1679233216878},"reference-count":17,"publisher":"Becaris Publishing Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To evaluate treatment patterns among elderly, newly diagnosed stage IV breast cancer patients receiving HER-2-targeted therapy.\n            <jats:bold>Methods:<\/jats:bold>\n            Women aged 65+ with an incident diagnosis of stage IV breast cancer (index) and no history of other cancer were identified from 2006 to 2010 linked Surveillance, Epidemiology and End Results and Medicare data. Continuous enrollment from 1 year preindex (baseline) through disenrollment, death or the end of the data (follow-up) was required. Patients were required to receive HER-2-targeted therapy (trastuzumab or lapatinib) during follow-up. Treatment therapies during follow-up were evaluated, as was the distribution of treatment combinations. Initial treatment regimens were evaluated based on the treatment(s) received after index. A 42-day gap in therapy or the addition of a biologic therapy was used as a marker for a subsequent regimen.\n            <jats:bold>Results:<\/jats:bold>\n            A total of 173 patients were identified (mean [standard deviation] age: 73.9 [6.7] years). The majority received trastuzumab (&gt;93%) during follow-up (mean [standard deviation] duration: 24.3 [11.3] months), with 9.8% receiving lapatinib. Most received chemotherapy (83.2%), approximately half received surgery (55.5%), over 40% received hormonal therapy and a third received radiation (35.3%). Trastuzumab + chemotherapy was the most common initial treatment regimen (43.9%); less common therapies include trastuzumab alone (17.3%), and trastuzumab + chemotherapy + hormonal (13.3%). Among patients receiving chemotherapy, the majority received a taxane-based chemotherapy. The average treatment duration for any treatment regimen was just less than a year (44.9\u201352.5 weeks).\n            <jats:bold>Conclusion:<\/jats:bold>\n            Among this population, the majority received taxane-based combination chemotherapy, consistent with National Comprehensive Cancer Network guidelines.\n          <\/jats:p>","DOI":"10.2217\/cer.14.39","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T12:43:28Z","timestamp":1414500208000},"page":"481-490","source":"Crossref","is-referenced-by-count":1,"title":["Treatment patterns among elderly patients with stage IV breast cancer treated with HER-2-targeted therapy"],"prefix":"10.57264","volume":"3","author":[{"given":"Kathleen","family":"Lang","sequence":"first","affiliation":[{"name":"Boston Health Economics, Inc., MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanni","family":"Hao","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, NJ 07936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Huang","sequence":"additional","affiliation":[{"name":"Boston Health Economics, Inc., MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Lin","sequence":"additional","affiliation":[{"name":"Boston Health Economics, Inc., MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaqueline Willemann","family":"Rogerio","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, NJ 07936, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Menzin","sequence":"additional","affiliation":[{"name":"Boston Health Economics, Inc., MA 02451, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"1","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel R","year":"2013","unstructured":"Siegel R , Naishadham D , Jemal A . Cancer statistics, 2013 . CA Cancer J. Clin. 63 ( 1 ), 11 \u2013 30 ( 2013 ).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","article-title":"Extending survival with chemotherapy in metastatic breast cancer","volume":"10","author":"O'Shaughnessy J","year":"2005","unstructured":"O'Shaughnessy J . Extending survival with chemotherapy in metastatic breast cancer . Oncologist 10 ( Suppl. 3 ), 20 \u2013 29 ( 2005 ).","journal-title":"Oncologist"},{"issue":"7","key":"e_1_3_4_5_2","first-page":"753","article-title":"NCCN Guidelines in Oncology: Breast Cancer v3.2013","volume":"11","author":"National Comprehensive Cancer Network","year":"2013","unstructured":"National Comprehensive Cancer Network . NCCN Guidelines in Oncology: Breast Cancer v3.2013 . NCCN 11 ( 7 ), 753 \u2013 760 ( 2013 ).","journal-title":"NCCN"},{"issue":"7","key":"e_1_3_4_6_2","first-page":"753","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer","volume":"11","author":"National Comprehensive Cancer Network","year":"2013","unstructured":"National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer . NCCN 11 ( 7 ), 753 \u2013 760 ( 2013 ).","journal-title":"NCCN"},{"issue":"3","key":"e_1_3_4_7_2","first-page":"166","article-title":"HER2-directed therapy for metastatic breast cancer","volume":"27","author":"Jelovac D","year":"2013","unstructured":"Jelovac D , Emens LA . HER2-directed therapy for metastatic breast cancer . Oncology 27 ( 3 ), 166 \u2013 175 ( 2013 ).","journal-title":"Oncology"},{"issue":"6","key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ctrv.2013.01.002","article-title":"HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials","volume":"39","author":"Dent S","year":"2013","unstructured":"Dent S , Oyan B , Honig A , Mano M , Howell S . HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials . Cancer Treat. Rev. 39 ( 6 ), 622 \u2013 631 ( 2013 ).","journal-title":"Cancer Treat. Rev."},{"issue":"16","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond EH","year":"2005","unstructured":"Romond EH , Perez EA , Bryant J Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N. Engl. J. Med. 353 ( 16 ), 1673 \u2013 1684 ( 2005 ).","journal-title":"N. Engl. J. Med."},{"issue":"9555","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith I","year":"2007","unstructured":"Smith I , Procter M , Gelber RD 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial . Lancet 369 ( 9555 ), 29 \u2013 36 ( 2007 ).","journal-title":"Lancet"},{"key":"e_1_3_4_11_2","article-title":"Surveillance Epidemiology and End Results","author":"National Cancer Institute","year":"2013","unstructured":"National Cancer Institute . Surveillance Epidemiology and End Results . SEER ( 2013 ). http:\/\/seer.cancer.gov\/","journal-title":"SEER"},{"key":"e_1_3_4_12_2","unstructured":"National Cancer Institute\n                                    . \n                                    Procedure Codes for SEER-Medicare Analyses\n                                     (\n                                    2013\n                                    ). \n                                    http:\/\/appliedresearch.cancer.gov\/seermedicare\/considerations\/procedure_codes.html"},{"key":"e_1_3_4_13_2","unstructured":"National Cancer Institute\n                                    . \n                                    Adjuvant and Neoadjuvant Therapy for Breast Cance\n                                    r (\n                                    2013\n                                    ). \n                                    www.cancer.gov\/cancertopics\/factsheet\/Therapy\/adjuvant-breast"},{"key":"e_1_3_4_14_2","volume-title":"Breast Cancer Symposium 2011.","author":"Taylor D","year":"2011","unstructured":"Taylor D , Sanon M , Clements K , Faria C , Balu S , Teitelbaum A . Treatment patterns and costs following metastatic breast cancer diagnosis in US women: a SEER-Medicare analysis . Presented at : Breast Cancer Symposium 2011. San Francisco, CA, USA , 8 September\u201310 September 2011 ."},{"issue":"8","key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1634\/theoncologist.2008-0288","article-title":"HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment","volume":"14","author":"Barron JJ","year":"2009","unstructured":"Barron JJ , Cziraky MJ , Weisman T , Hicks DG . HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment . Oncologist 14 ( 8 ), 760 \u2013 768 ( 2009 ).","journal-title":"Oncologist"},{"issue":"9","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3109\/07357907.2011.616251","article-title":"Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab","volume":"29","author":"Griffiths RI","year":"2011","unstructured":"Griffiths RI , Lalla D , Herbert RJ , Doan JF , Brammer MG , Danese MD . Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab . Cancer Invest. 29 ( 9 ), 573 \u2013 584 ( 2011 ).","journal-title":"Cancer Invest."},{"issue":"1","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-012-2329-5","article-title":"Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004\u20132007","volume":"137","author":"Kurian AW","year":"2013","unstructured":"Kurian AW , Lichtensztajn DY , Keegan TH Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004\u20132007 . Breast Cancer Res. Treat. 137 ( 1 ), 247 \u2013 260 ( 2013 ).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10549-012-2209-z","article-title":"Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study","volume":"135","author":"Kaufman PA","year":"2012","unstructured":"Kaufman PA , Brufsky AM , Mayer M Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study . Breast Cancer Res. Treat. 135 ( 3 ), 875 \u2013 883 ( 2012 ).","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","article-title":"A review of uses of health care utilization databases for epidemiologic research on therapeutics","volume":"58","author":"Schneeweiss S","year":"2005","unstructured":"Schneeweiss S , Avorn J . A review of uses of health care utilization databases for epidemiologic research on therapeutics . J. Clin. Epidemiol. 58 ( 4 ), 323 \u2013 337 ( 2005 ).","journal-title":"J. Clin. Epidemiol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer.14.39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:59:52Z","timestamp":1679230792000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer.14.39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.2217\/cer.14.39"],"URL":"https:\/\/doi.org\/10.2217\/cer.14.39","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}